Article
Bridging the Gaps in Complex Patient Journeys by Enriching Data
John Giannouris, Senior Director of Specialty Pharma Data Strategy & Consulting Services, IQVIA; Hilary Scannapieco, Senior Director of Patient Solutions Sales, IQVIA
Jul 16, 2021

Summary

As the number of specialty drugs expands in complex disease areas, such as autoimmune, multiple sclerosis, oncology, and respiratory illnesses, pharmaceutical companies have shown an increased interest in tracking and understanding real world and clinical data throughout the patient journey to support more targeted decision-making. There are significant challenges in the journeys that patients with complex diseases experience, including gaps, lapses, or delays in therapy. This often includes the initial start of a treatment, as well as when switching to a next-line therapy. These delays or gaps can not only lead to negative impacts for the patients but can affect the manufacturers as well. When specialty product pharmaceutical companies enrich their understanding of the patient journey through aggregated and integrated data, they will be more apt in improving treatment outcomes and making smarter decisions.

Read more - Bridging the Gaps in Complex Patient Journeys by Enriching Data.

Contact Us